ARMP

Armata Pharmctcl

• NASDAQ·06/23 14:32

  Armata Receives $2.5 Mln From DoD For AP-SA02 In Treating Bacteremia; Phase 3 Planned For H2 2026

• Seeking Alpha·06/23 14:27

  Armata gains $2.5M extra funding from DoD for lead program

• TipRanks·06/23 12:14

  Armata Pharmaceuticals granted $2.5M additional non-dilutive award funding

• Dow Jones·06/23 11:34

  Armata Pharmaceuticals Shares Rise on Additional $2.5M Government Grant

• TipRanks·06/23 11:31

  Armata gains new DoD funding for AP-SA02 advancement

• Benzinga·06/23 11:12

  Armata Pharma Receives Additional $2.5M Of Non-Dilutive DoD Funding Via Medical Technology Enterprise Consortium, Managed By Naval Medical Research Command

• TipRanks·06/16 21:30

  Armata Shareholders Approve Directors, Executive Pay and Auditor

• TipRanks·05/28 00:26

  Analyst Reiterates Buy on Armata, Maintaining $20 Price Target Ahead of Pivotal Phase 3 AP-SA02 Trial

• TipRanks·05/14 10:44

  H.C. Wainwright Reaffirms Their Buy Rating on Armata Pharmaceuticals (ARMP)

• TipRanks·05/13 22:17

  Armata Secures New Loan Amid Wider Quarterly Loss

• TipRanks·05/13 21:41

  Armata Pharmaceuticals reports Q1 EPS ($3.16) vs. (20c) last year

• Seeking Alpha·05/13 20:53

  Armata Pharmaceuticals GAAP EPS of -$3.16 misses by $2.78, revenue of $0.79M

• Benzinga·05/13 20:42

  Armata Pharmaceuticals Q1 EPS $(3.16) Misses $(0.38) Estimate, Sales $789.000K Up From $491.000K YoY

• Dow Jones·05/13 20:42

  *Armata Pharma Entered Into Secured Credit Agreement With Innoviva for $25 M Maturing in 2029 >ARMP

• Dow Jones·05/13 20:41

  *Armata Pharmaceuticals 1Q Loss $115.3M >ARMP